Home Recombinant HDL (Milano) protects endotoxin-challenged rats from multiple organ injury and dysfunction
Article
Licensed
Unlicensed Requires Authentication

Recombinant HDL (Milano) protects endotoxin-challenged rats from multiple organ injury and dysfunction

  • Xinbo Zhang , Luya Wang and Baosheng Chen EMAIL logo
Published/Copyright: September 3, 2014

Abstract

Endotoxemia, the systemic inflammatory host response to infection, leads to severe septic shock and multiple organ injury and dysfunction syndrome (MOPS), which cause mortality. Apolipoprotein A-IMilano (apoAIM), a naturally occurring cysteine mutant of apoAI with dimers as its effective form, showed an enhanced cardiovascular protective activity compared with wild-type apoAI (apoAIwt). To investigate the role of recombinant high-density lipoprotein (rHDL) reconstituted with apoAIM (rHDLM) on endotoxemia and MOPS, we examined the anti-inflammatory, anti-oxidant, and protective effects of this cysteine mutant against organ injury in endotoxin-challenged rat models compared with rHDLwt. In the present study, we demonstrated for the first time that pretreatment with rHDLM significantly attenuated liver and renal dysfunction and histopathological features of lung injury in endotoxin-challenged endotoxemia rats. Administration of rHDLM to endotoxemia rats dramatically suppressed proinflammatory cytokines and adhesion molecule increase in tumor necrosis factor α, interleukin 1β, interleukin 6, and intercellular adhesion molecule 1. In addition, rHDLM pretreatment inhibited lipid peroxidation and enhanced total antioxidant capacity in vivo. In comparison with rHDLwt, rHDLM showed enhanced capacity on anti-inflammatory and anti-oxidant functions. In summary, administration of rHDLM protected endotoxin-challenged endotoxemia and MOPS through enhanced anti-inflammatory and anti-oxidant properties.


Corresponding author: Baosheng Chen, National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Department of Biochemistry and Molecular Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, 5 Dong Dan San Tiao, Beijing 100005, China, e-mail:

Acknowledgments

This work was supported by a National Basic Research Grant 973 of China (2006)CB503801). The authors gratefully acknowledge the technical assistance and helpful suggestions of Hong Xue and Gang Wu.

References

Angus, D.C., Linde-Zwirble, W.T., Lidicker, J., Clermont, G., Carcillo, J., and Pinsky, M.R. (2001). Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303–1310.10.1097/00003246-200107000-00002Search in Google Scholar

Ansell, B.J., Navab, M., Watson, K.E., Fonarow, G.C., and Fogelman, A.M. (2004). Anti-inflammatory properties of HDL. Rev. Endocr. Metab. Disord. 5, 351–358.10.1023/B:REMD.0000045107.71895.b2Search in Google Scholar

Baker, P.W., Rye, K.A., Gamble, J.R., Vadas, M.A., and Barter, P.J. (2000). Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J. Lipid Res. 41, 1261–1267.10.1016/S0022-2275(20)33434-9Search in Google Scholar

Bhattacharyya, J., Biswas, S., and Datta, A.G. (2004). Mode of action of endotoxin: role of free radicals and antioxidants. Curr. Med. Chem. 11, 359–368.10.2174/0929867043456098Search in Google Scholar

Bielicki, J.K. and Oda, M.N. (2002). Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry 41, 2089–2096.10.1021/bi011716pSearch in Google Scholar

Cockerill, G.W., Huehns, T.Y., Weerasinghe, A., Stocker, C., Lerch, P.G., Miller, N.E., and Haskard, D.O. (2001). Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation. 103, 108–112.10.1161/01.CIR.103.1.108Search in Google Scholar

Franceschini, G., Calabresi, L., and Sirtori, C.R. (1988). Apolipoprotein AI-Milano: altered lipid binding properties in a human apolipoprotein variant. Prog. Clin. Biol. Res. 255, 73–80.Search in Google Scholar

Garca, M.F., Aslan, M., Tuna, B., Kozan, A., and Cankaya, H. (2013). Serum myeloperoxidase activity, total antioxidant capacity and nitric oxide levels in patients with chronic otitis media. J. Membr. Biol. 246, 519–524.10.1007/s00232-013-9561-8Search in Google Scholar

Hasegawa, N., Kandra, T.G., Husari, A.W., Veiss, S., Hart, W.T., Hedgpeth, J., Wydro, R., and Raffin, T.A. (1996). The effects of recombinant human thrombomodulin on endotoxin-induced multiple-system organ failure in rats. Am. J. Respir. Crit. Care Med. 153, 1831–1837.10.1164/ajrccm.153.6.8665042Search in Google Scholar

Haveman, J.W., Muller, Kobold, A.C., Tervaert, J.W., van den Berg, A.P., Tulleken, J.E., Kallenberg, C.G., and The, T.H. (1999). The central role of monocytes in the pathogenesis of sepsis: consequences for immunomonitoring and treatment. Neth. J. Med. 55, 132–141.10.1016/S0300-2977(98)00156-9Search in Google Scholar

Hubsch, A.P., Casas, A.T., and Doran, J.E. (1995). Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models. J. Lab. Clin. Med. 126, 548–558.Search in Google Scholar

Ibanez, B., Vilahur, G., Cimmino, G., Speidl, W.S., Pinero, A., Choi, B.G., Zafar, M.U., Santos-Gallego, C.G., Krause, B., Badimon, L., et al. (2008). Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. J. Am. Coll. Cardiol. 51, 1104–1109.10.1016/j.jacc.2007.09.071Search in Google Scholar PubMed

Ibanez, B., Giannarelli, C., Cimmino, G., Santos-Gallego, C.G., Alique, M., Pinero, A., Vilahur, G., Fuster, V., Badimon, L., and Badimon, J.J. (2012). Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). Atherosclerosis 220, 72–77.10.1016/j.atherosclerosis.2011.10.006Search in Google Scholar PubMed

Luscher, T.F., Landmesser, U., von Eckardstein, A., and Fogelman, A.M. (2014). High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ. Res. 114, 171–182.10.1161/CIRCRESAHA.114.300935Search in Google Scholar PubMed

McDonald, M.C., Dhadly, P., Cockerill, G.W., Cuzzocrea, S., Mota-Filipe, H., Hinds, C.J., Miller, N.E., and Thiemermann, C. (2003). Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock. Shock 20, 551–557.10.1097/01.shk.0000097249.97298.a3Search in Google Scholar PubMed

Moore, R.E., Navab, M., Millar, J.S., Zimetti, F., Hama, S., Rothblat, G.H., and Rader, D.J. (2005). Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ. Res. 97, 763–771.10.1161/01.RES.0000185320.82962.F7Search in Google Scholar PubMed

Oda, M.N., Bielicki, J.K., Berger, T., and Forte, T.M. (2001). Cysteine substitutions in apolipoprotein A-I primary structure modulate paraoxonase activity. Biochemistry 40, 1710–1718.10.1021/bi001922hSearch in Google Scholar PubMed

Pajkrt, D., Doran, J.E., Koster, F., Lerch, P.G., Arnet, B., van der Poll, T., ten Cate, J.W., and van Deventer, S.J. (1996). Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J. Exp. Med. 184, 1601–1608.10.1084/jem.184.5.1601Search in Google Scholar PubMed PubMed Central

Parker, T.S., Levine, D.M., Chang, J.C., Laxer, J., Coffin, C.C., and Rubin, A.L. (1995). Reconstituted high-density lipoprotein neutralizes gram-negative bacterial lipopolysaccharides in human whole blood. Infect. Immun. 63, 253–258.10.1128/iai.63.1.253-258.1995Search in Google Scholar PubMed PubMed Central

Sakaguchi, S. and Furusawa, S. (2006). Oxidative stress and septic shock: metabolic aspects of oxygen-derived free radicals generated in the liver during endotoxemia. FEMS Immunol. Med. Microbiol. 47, 167–177.10.1111/j.1574-695X.2006.00072.xSearch in Google Scholar PubMed

Shah, P.K., Nilsson, J., Kaul, S., Fishbein, M.C., Ageland, H., Hamsten, A., Johansson, J., Karpe, F., and Cercek, B. (1998). Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 97, 780–785.10.1161/01.CIR.97.8.780Search in Google Scholar

Speidl, W.S., Cimmino, G., Ibanez, B., Elmariah, S., Hutter, R., Garcia, M.J., Fuster, V., Goldman, M.E., and Badimon, J.J. (2010). Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. Eur. Heart J. 31, 2049–2057.10.1093/eurheartj/ehq064Search in Google Scholar PubMed

Tall, A.R. (1990). Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J. Clin. Invest. 86, 379–384.10.1172/JCI114722Search in Google Scholar

Valko, M., Leibfritz, D., Moncol, J., Cronin, M.T., Mazur, M., and Telser, J. (2007). Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39, 44–84.10.1016/j.biocel.2006.07.001Search in Google Scholar

Weisgraber, K.H., Rall, S.C. Jr., Bersot, T.P., Mahley, R.W., Franceschini, G., and Sirtori, C.R. (1983). Apolipoprotein A-IMilano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I. J. Biol. Chem. 258, 2508–2513.10.1016/S0021-9258(18)32955-7Search in Google Scholar

Wheeler, A.P. and Bernard, G.R. (1999). Treating patients with severe sepsis. N. Engl. J. Med. 340, 207–214.10.1056/NEJM199901213400307Search in Google Scholar PubMed

Wurfel, M.M., Kunitake, S.T., Lichenstein, H., Kane, J.P., Wright, and S.D. (1994). Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J. Exp. Med. 180, 1025–1035.10.1084/jem.180.3.1025Search in Google Scholar PubMed PubMed Central

Yan, Y.J., Li, Y., Lou, B., and Wu, M.P. (2006). Beneficial effects of ApoA-I on LPS-induced acute lung injury and endotoxemia in mice. Life Sci. 79, 210–215.10.1016/j.lfs.2006.02.011Search in Google Scholar PubMed

Zhang, X. and Chen, B. (2010). Recombinant high density lipoprotein reconstituted with apolipoprotein AI cysteine mutants as delivery vehicles for 10-hydroxycamptothecin. Cancer Lett. 298, 26–33.10.1016/j.canlet.2010.05.023Search in Google Scholar PubMed

Zhang, X., Zhu, X., and Chen, B. (2010). Inhibition of collar-induced carotid atherosclerosis by recombinant apoA-I cysteine mutants in apoE-deficient mice. J. Lipid. Res. 51, 3434–3442.10.1194/jlr.M008573Search in Google Scholar PubMed PubMed Central

Zhu, X., Wu, G., Zeng, W., Xue, H., and Chen, B. (2005). Cysteine mutants of human apolipoprotein A-I: a study of secondary structural and functional properties. J. Lipid. Res. 46, 1303–1311.10.1194/jlr.M400401-JLR200Search in Google Scholar PubMed


Supplemental Material

The online version of this article (DOI 10.1515/hsz-2014-0188) offers supplementary material, available to authorized users.


Received: 2014-4-19
Accepted: 2014-5-30
Published Online: 2014-9-3
Published in Print: 2015-1-1

©2014 by De Gruyter

Downloaded on 29.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/hsz-2014-0188/html?lang=en
Scroll to top button